HIA
AMRX icon

HFM Investment Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

HFM Investment Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416 Buy
24
+15
+167% +$206 ﹤0.01% 1052
2026
Q1 		$112 Hold
9
– – ﹤0.01% 1106
2025
Q4 		$114 Hold
9
– – ﹤0.01% 1155
2025
Q3 		$90 Hold
9
– – ﹤0.01% 1174
2025
Q2 		$73 Buy
9
+7
+350% +$53 ﹤0.01% 1190
2025
Q1 		$17 Buy
+2
New +$17 ﹤0.01% 1165

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

HFM Investment Advisors's AMRX Position: Q2 2026 in Review

HFM Investment Advisors increased its Amneal Pharmaceuticals (AMRX) stake by 167% in Q2 2026, buying an estimated $206 and bringing the position to 24 shares worth $416. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

HFM Investment Advisors first reported a position in AMRX in Q1 2025 and has held it in 6 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • HFM Investment Advisors held 24 shares of Amneal Pharmaceuticals worth $416 as of Q2 2026.
  • HFM Investment Advisors bought 15 Amneal Pharmaceuticals shares in Q2 2026, an estimated $206.
  • Amneal Pharmaceuticals made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1052 holding.
  • HFM Investment Advisors first reported a position in Amneal Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.